# Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis

> **NCT02245360** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 107 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Phleum pratense grass pollen allergen extract
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02245360
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2016-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02245360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02245360, "Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02245360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*